Arsenical keratosis

Definition

AK is a pre-cancerous skin condition caused by longterm poisoning with arsenic.

Signs and symptoms

AK typically presents with small yellow corn-like warty bumps in the skin preceded by dark marks. It is frequently seen on the sides of the palms of hands, and base and sides of fingers and feet. The dark marks may look like 'raindrops' and these may be associated with Mees' lines across the nails. The bumps typically appear 20 to 30 years after exposure to arsenic from usually a herbal medicine or contaminated water from wells.

AK may precede the development of squamous cell carcinoma or basal cell carcinoma.

Pathophysiology

Arsenite impairs nucleotide excision repair, and it may also affect gene expression by increasing or decreasing DNA methylation. The high affinity of arsenic for sulfhydryl groups makes keratin-rich cells (e.g., epidermal keratinocytes) a sensitive target for arsenic-induced toxicity. Arsenic has been shown to alter epidermal keratinocyte differentiation processes, induce overexpression of growth factors, and enhance proliferation of human keratinocytes.

Differential diagnosis

Actinic keratosis, seborrhoic keratosis, and squamous cell carcinoma in situ may appear similar.

Treatment

• A chelating agent (e.g., dimercaprol) may be helpful to correct acute arsenic exposure, but it has minimal or no effect for patients who had arsenic exposure a long time ago.
• Oral retinoids (e.g., acitretin, etretinate) may be helpful in treating arsenic-induced cutaneous lesions and in reducing the risk of cutaneous and internal malignancy formation, especially in Bowman's disease.
• Topical 5-fluorouracil cream or 5% imiquimod cream may be useful in treating arsenical keratoses and Bowen's disease.

References

References

1. Freedberg, et al. (2003). ''Fitzpatrick's Dermatology in General Medicine''. (6th ed.). McGraw-Hill. {{ISBN. 0-07-138076-0.
2. (July 2005). "Arsenic geochemistry and health". [[Environ Int]].
3. James, William D.. (2006). "Andrews' Diseases of the Skin: clinical Dermatology". Saunders Elsevier.
4. (February 2002). "Treatment of arsenical keratosis and Bowen's disease with acitretin". [[Int. J. Dermatol.]].
5. (January 2004). "Arsenic toxicity, mutagenesis, and carcinogenesis--a health risk assessment and management approach". [[Mol. Cell. Biochem.]].
6. (2024). "Arsenical Keratosis". StatPearls Publishing.
7. (2018). "WHO Classification of Skin Tumours". World Health Organization.
8. (2020). "Andrews' Diseases of the Skin: Clinical Dermatology". Elsevier.
9. (February 1997). "Interaction of arsenic(III) with nucleotide excision repair in UV-irradiated human fibroblasts". [[Carcinogenesis (journal).
10. (November 1994). "Arsenate perturbation of human keratinocyte differentiation". [[Cell Growth Differ.]].
11. (November 1996). "Arsenic induces overexpression of growth factors in human keratinocytes". [[Toxicol. Appl. Pharmacol.]].
12. (March 2008). "Successful treatment of palmoplantar arsenical keratosis with a combination of keratolytics and low-dose acitretin". [[Clin. Exp. Dermatol.]].
13. (October 2003). "Successful treatment of multiple premalignant and malignant lesions in arsenical keratosis with a combination of acitretin and intralesional 5-fluorouracil". [[J. Dermatol.]].
14. (1983). "Treatment of arsenical keratosis with etretinate". [[Acta Derm. Venereol.]].
15. Boonchai W. (April 2006). "Treatment of precancerous and cancerous lesions of chronic arsenicism with 5% imiquimod cream". [[Arch Dermatol]].